<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231318</url>
  </required_header>
  <id_info>
    <org_study_id>Cingal 19-01</org_study_id>
    <nct_id>NCT04231318</nct_id>
  </id_info>
  <brief_title>Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anika Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anika Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, parallel group, placebo controlled trial to&#xD;
      evaluate the contribution of Triamcinolone Hexacetonide (TH) to pain relief, both in terms of&#xD;
      magnitude and duration, when used within a single injection of Cingal® compared to a single&#xD;
      injection of TH in subjects with OA of the knee.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in baseline WOMAC (Western Ontario and McMaster Universities Arthritis Index) pain score</measure>
    <time_frame>26 Weeks</time_frame>
    <description>The change from Baseline in knee pain as measured by the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) Pain Score (Range 0 mm No Pain to 100 mm Worst Pain) at 26 weeks post treatment comparing the Cingal® arm to the TH arm, the Cingal arm to the Placebo arm, and the TH arm to the Placebo arm.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">231</enrollment>
  <condition>Osteo Arthritis Knee</condition>
  <arm_group>
    <arm_group_label>Cingal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone Hexacetonide (TH) - Lederlon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cingal</intervention_name>
    <description>A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH)</description>
    <arm_group_label>Cingal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Hexacetonide - Lederlon</intervention_name>
    <description>20 mg/ml supplied as 1 mL unit dose of Triamcinolone Hexacetonide</description>
    <arm_group_label>Triamcinolone Hexacetonide (TH) - Lederlon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is 40-75 years old.&#xD;
&#xD;
          2. Body Mass Index (BMI) ≤ 40 kg/m2.&#xD;
&#xD;
          3. Subject has Kellgren-Lawrence (K-L) severity grade II or III in the Index knee as&#xD;
             determined by X-Ray. Contralateral knee: K-L severity grade 0, I or II.&#xD;
&#xD;
          4. Subject has had at least two signs and at least two symptoms of OA disease (based on&#xD;
             the European League Against Rheumatism (EULAR) recommendations for diagnosing knee OA)&#xD;
             in the Index knee for at least 6 months despite conservative treatment (weight&#xD;
             reduction, physical therapy, pain medications, etc.). The EULAR signs and symptoms are&#xD;
             as follows:&#xD;
&#xD;
               -  Signs: crepitus, restricted movement and bony enlargement&#xD;
&#xD;
               -  Symptoms: persistent knee pain, limited morning stiffness and reduced function&#xD;
&#xD;
          5. Subject must be willing to abstain from other IA treatments of the knee for the&#xD;
             duration of the study.&#xD;
&#xD;
          6. Subject is willing to discontinue all analgesics including nonsteroidal&#xD;
             anti-inflammatory drugs (NSAIDs), except acetaminophen before the treatment injection&#xD;
             and through the completion of the study. NSAIDs should be discontinued through the&#xD;
             Screening period.&#xD;
&#xD;
          7. Subject is willing to use only acetaminophen (up to a maximum of 3.0 grams per day)&#xD;
             for the treatment of joint pain for the duration of the study. At least forty-eight&#xD;
             hours prior to the Baseline Visit and each follow-up visit, the Subject is willing to&#xD;
             discontinue use of acetaminophen&#xD;
&#xD;
          8. Subject is willing to maintain a stable dose of oral glucosamine and/or chondroitin&#xD;
             sulfate products throughout the study, if taken prior to signing ICF.&#xD;
&#xD;
          9. Subject is able to understand and comply with the requirements of the study and&#xD;
             voluntarily provides consent.&#xD;
&#xD;
        Baseline Inclusion Criteria 24 Subject has a Western Ontario and McMaster Universities&#xD;
        Osteoarthritis Index (WOMAC) pain-sub-score ≥ 50 mm and ≤ 90 mm in the affected knee and ≤&#xD;
        30 mm in the contralateral knee on a 100 mm Visual Analog Scale (VAS) scale.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject received an IA injection of Hyaluronic Acid (HA) and/or steroid in either knee&#xD;
             within 6 months of signing the ICF. A Subject will be excluded if they are planning to&#xD;
             receive an HA or steroid injection (other than the study injection) in either knee&#xD;
             during the course of this study.&#xD;
&#xD;
          2. Subject had an arthroscopy of either knee within 3 months of signing the ICF.&#xD;
&#xD;
          3. Subject had an open surgical procedure of either knee or hip or any surgery of the&#xD;
             spine within 12 months of signing ICF. Subject plans to have knee, hip or spine&#xD;
             surgery within the study period.&#xD;
&#xD;
          4. Subject has intra-articular trauma to the Index knee. Subject has concurrent&#xD;
             multi-system or multi-limb trauma.&#xD;
&#xD;
          5. Subject has evidence or medical history of the following diseases in the Index knee:&#xD;
             septic arthritis; inflammatory joint disease; history of Reiter's syndrome; gout;&#xD;
             chondrocalcinosis associated with recurrent episodes of acute synovitis of the knee&#xD;
             consistent with pseudogout; osteochondritis dissecans, Paget disease of the bone;&#xD;
             ochronosis; acromegaly; hemochromatosis; primary osteochondromatosis; known history of&#xD;
             Wilson disease; heritable disorders or collagen gene mutations.&#xD;
&#xD;
          6. Subject has a history of cartilage repair surgery in the Index knee within 3 years of&#xD;
             signing the ICF.&#xD;
&#xD;
          7. Subject has a history of Anterior cruciate ligament (ACL) repair, reconstruction or&#xD;
             injury in the Index knee within 3 years of signing the ICF.&#xD;
&#xD;
          8. Subject has X-Ray findings of acute fractures, severe bone loss, avascular necrosis,&#xD;
             severe bone or joint deformity in the Index knee.&#xD;
&#xD;
          9. Subject has significant varus or valgus deformity greater than 8 degrees in either&#xD;
             knee.&#xD;
&#xD;
         10. Subject has a clinically apparent tense effusion of the Index knee.&#xD;
&#xD;
         11. Subject has knee instability in either knee per the Investigator's assessment.&#xD;
&#xD;
         12. Subject requires consistent use of an assistive device (e.g. wheelchair, walker, etc.)&#xD;
             Occasional use of a cane is acceptable.&#xD;
&#xD;
         13. Subject has medical condition(s) which could affect study assessments or may adversely&#xD;
             affect the safety and/or success of the study treatment. This includes but is not&#xD;
             limited to the following: a. Peripheral neuropathy severe enough to interfere with&#xD;
             evaluation of the subject, b. Vascular insufficiency severe enough to interfere with&#xD;
             evaluation of the subject, c. Active fibromyalgia, d. Hemiparesis involving either&#xD;
             lower extremity, e. Immunocompromised or immunosuppressive disorder or receiving&#xD;
             medications to treat immunosuppressive disorders, f. Systemic bleeding disorder(s), g.&#xD;
             Current malignancy or treatment within the last 5 years, except for non-melanoma skin&#xD;
             cancer, h. Significant psychiatric disorder, i. Active drug and/or alcohol abuse&#xD;
             within the past year, j. Uncontrolled diabetes with a Screening Hemoglobin A1C (HbA1c)&#xD;
             of &gt;7% k. contraindication to Triamcinolone Hexacetonide (TH) including active&#xD;
             tuberculosis, herpes simplex keratitis, acute psychoses and systemic mycoses and&#xD;
             paracitoses.&#xD;
&#xD;
         14. Subject is taking medications at the time the subjects signs the ICF which could&#xD;
             interfere with the treatment procedure, healing and/or assessments. This includes but&#xD;
             is not limited to oral or injectable anticoagulant treatments, anti-aggregant platelet&#xD;
             treatment, chronic opioid analgesics. Low dose aspirin used for cardiovascular&#xD;
             protection is allowed if a stable regimen is maintained for the duration of the study.&#xD;
&#xD;
         15. Subject is receiving treatment using electromagnetic stimulation and/or low intensity&#xD;
             ultrasound in the Index knee at the time of signing the ICF, within 3 months of&#xD;
             signing the ICF or plans to receive treatment any time during the study period.&#xD;
&#xD;
         16. Subjects who had an oral, intramuscular, intravenous, rectal suppository or topical&#xD;
             (excluded in Index knee only) corticosteroid within 30 days of signing the ICF are&#xD;
             excluded. Topical corticosteroid use at any site other than the Index knee is allowed.&#xD;
&#xD;
         17. Subject has a pre-treatment contraindication to IA injections or aspiration of the&#xD;
             Index knee, including cutaneous infection in the injection site area, active IA&#xD;
             infection (as suggested by moderate or marked effusion), knee deformity or condition&#xD;
             which, in the opinion of the Investigator could jeopardize the sterility or delivery&#xD;
             of the IA injection.&#xD;
&#xD;
         18. Subjects with a history of hypersensitivity to any of the ingredients in the&#xD;
             hyaluronan or previous hypersensitivity to the administration of corticosteroids or an&#xD;
             inability to tolerate acetaminophen.&#xD;
&#xD;
         19. Subject has any contraindication to the receipt of a corticosteroid.&#xD;
&#xD;
         20. Subject is receiving or in litigation for worker's compensation.&#xD;
&#xD;
         21. Subject is a woman who is pregnant or breastfeeding at the Screening Visit or a woman&#xD;
             of child bearing potential who refuses to use effective contraception during the&#xD;
             course of the study.&#xD;
&#xD;
         22. Subject was involved in any other research study involving an investigational product,&#xD;
             or a new application of an approved product, within 60 days of signing the ICF.&#xD;
&#xD;
         23. Subject previously treated with Cingal for knee osteoarthritis.&#xD;
&#xD;
        Baseline Exclusion Criteria 25. Subject has a decrease of ≥ 20 mm in the WOMAC&#xD;
        pain-sub-score (average of 5 pain scales) from Screening to Baseline in the Index knee on a&#xD;
        100 mm Visual Analog Scale (VAS) scale.&#xD;
&#xD;
        26. Subject has a synovial fluid aspirate volume &gt; 10 mL in the Index knee. 27. Subject has&#xD;
        a contraindication to continue with the study treatment injection based on the visual&#xD;
        appearance of the synovial fluid aspirate unless the fluid is examined microscopically&#xD;
        prior to injection with no clinically significant findings (e.g. bacteria, crystals or&#xD;
        blood).&#xD;
&#xD;
        28. Subject has range of motion of less than 100° flexion in either knee.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adrian Orr</last_name>
    <phone>781-457-9226</phone>
    <email>aorr@anika.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carol Pekar</last_name>
    <phone>781-457-9218</phone>
    <email>cpekar@anika.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Orthopaedic Specialist of North America, PLLC DBA OrthoArizona</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vianeth Santiago</last_name>
      <phone>800-774-1534</phone>
      <email>v.santiago@prgresearch.com</email>
    </contact>
    <investigator>
      <last_name>Kipling Sharpe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Bone and Joint Specialists</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vianeth Santiago</last_name>
      <phone>800-774-1534</phone>
      <email>v.santiago@prgresearch.com</email>
    </contact>
    <investigator>
      <last_name>Eric Eifler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tucson Orthopaedic Institute</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jelena Candito</last_name>
      <phone>520-784-6446</phone>
      <email>jcandito@tucsonortho.com</email>
    </contact>
    <investigator>
      <last_name>Nebojsa Skrepnik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Research Center, Inc.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiynn Nguyen</last_name>
      <phone>714-999-6688</phone>
      <email>hnguyen@arctrials.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91722</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Rodriguez</last_name>
      <phone>626-869-5730</phone>
      <email>m.rodriguez@medvinresearch.com</email>
    </contact>
    <investigator>
      <last_name>Samy Metyas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Core Orthopaedic Medical Center (San Dieguito Orthopedic Medical Center)</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farouk Awad</last_name>
      <phone>760-943-6700</phone>
      <email>fawad@coreorthopaedic.com</email>
    </contact>
    <investigator>
      <last_name>Gregory Loren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research</name>
      <address>
        <city>Norco</city>
        <state>California</state>
        <zip>92860</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Cook</last_name>
      <phone>714-252-6689</phone>
      <email>Michele.cook@dreamteamresearch.com</email>
    </contact>
    <investigator>
      <last_name>Peter Mattar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dream Team Clinical Research</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Country Cook</last_name>
      <phone>714-780-0076</phone>
      <email>Courtney.Cook@dreamteamresearch.com</email>
    </contact>
    <investigator>
      <last_name>Quang Vo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Probe Clinical Research Corporation</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paris Peithmann</last_name>
      <phone>949-355-4226</phone>
      <email>Paris.Probe@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gary Pang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research, Riverside</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Nari</last_name>
      <phone>855-367-8834</phone>
      <email>dneri@artemis-research.com</email>
    </contact>
    <investigator>
      <last_name>Sarah Lavery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research, San Marcos</name>
      <address>
        <city>Summerville</city>
        <state>California</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruby Casillas</last_name>
      <phone>858-278-3647</phone>
      <phone_ext>342</phone_ext>
      <email>rcasillas@artemis-research.com</email>
    </contact>
    <investigator>
      <last_name>Stacey Layle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Tujunga</city>
        <state>California</state>
        <zip>91042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Robleto</last_name>
      <phone>213-281-5146</phone>
      <email>melanie@medvinresearch.com</email>
    </contact>
    <investigator>
      <last_name>Dan La, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nereyda Negrete</last_name>
      <phone>562-758-6600</phone>
      <email>nereyda@medvinresearch.com</email>
    </contact>
    <investigator>
      <last_name>Tien I Su, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consulting</name>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <zip>06460</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Medical Research Inc</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Stopnytsky</last_name>
      <phone>727-724-3316</phone>
      <email>kim@tbmr.net</email>
    </contact>
    <investigator>
      <last_name>Sureka Bollepalli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shrock Research</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Shrock</last_name>
      <phone>954-626-3743</phone>
      <email>Natalie@shrockresearch.com</email>
    </contact>
    <investigator>
      <last_name>Kevin Shrock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pines Clinical Research, Inc</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Varon</last_name>
      <phone>954-435-9990</phone>
      <email>jennifervaron@pinesclinical.com</email>
    </contact>
    <investigator>
      <last_name>Steven Zeig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension Research</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Mack</last_name>
      <phone>727-521-9200</phone>
      <email>lmack@adventcrc.com</email>
    </contact>
    <investigator>
      <last_name>Dale Bramlet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research, LLC</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Parillon</last_name>
      <phone>954-915-9991</phone>
      <email>ginap@pcrflorida.com</email>
    </contact>
    <investigator>
      <last_name>Richard M Linn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Wilmsen</last_name>
      <phone>312-503-2315</phone>
      <email>katie.wilmsen@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Schnitzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Best Clinical Trials, LLC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lydia Birkhoff</last_name>
      <phone>504-897-5211</phone>
      <email>lbirkhoffbct@gmail.com</email>
    </contact>
    <investigator>
      <last_name>George Walker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research Associates, LLC</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Helwig</last_name>
      <phone>716-626-6320</phone>
      <email>upstatemaureen@aol.com</email>
    </contact>
    <investigator>
      <last_name>James Wild, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bailey Jordan</last_name>
      <phone>910-815-6108</phone>
      <email>Bailey.jordan@pmg-research.com</email>
    </contact>
    <investigator>
      <last_name>Claudius Jarrett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center (CCRC)</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464-3803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki Shebelskie</last_name>
      <phone>843-856-3784</phone>
      <email>nshebelskie@coastalcarolinaresearch.com</email>
    </contact>
    <investigator>
      <last_name>Shailesh Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Research</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Corvino</last_name>
      <phone>843-851-7098</phone>
      <email>rrcorvino@palmettoprimarycare.com</email>
    </contact>
    <investigator>
      <last_name>Colby Grossman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Medical, Inc.</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christi Stephens</last_name>
      <phone>434-793-4711</phone>
      <email>Christi.Stephens@spectrummed.com</email>
    </contact>
    <investigator>
      <last_name>Mark Hermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

